Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the progression-free survival (PFS) of the drug
combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated
participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable,
locally-recurrent or metastatic breast cancer.